
Record High Strategies 10/24/25
Halftime Report
00:00
Merck and Healthcare Dividend Opportunities
Kevin discusses buying Merck for acquisition upside, dividend yield, and recovery as Keytruda patent concerns ease.
Play episode from 31:16
Transcript


